After a 'pivotal' year, AMRI expects another leap in 2014

Former Teva exec William Marth is the new CEO of AMRI
AMRI CEO William Marth

Last year, Albany, NY, contract developer AMRI ($AMRI) watched its founding CEO retire and its business model evolve, shifting its priorities to deliver a jump in revenue, and now the company believes it's on track for bigger growth in 2014.

AMRI raked in $246.6 million on the year, a 9% increase over 2012, with net income coming in at $12.7 million to beat out the prior year's $3.8 million loss. Leading the way was the company's large-scale manufacturing business, which grew 14% to $132.6 million, followed by its discovery and small-scale segment, which increased 5% to $77.4 million. Royalty revenue, which once accounted for much of AMRI's business, ticked up just 2% to $36.6 million.

But AMRI's ability to count on cuts of clients' drugs to boost profits is soon to be a thing of the past, as the company is expecting royalty revenue to plummet 29% in 2014. However, ex-CEO Thomas D'Ambra more than prepared for the shift, and, with a "pivotal" year in the books, AMRI has positioned itself to cash in on a boom in contract manufacturing, new chief William Marth said, expecting between 10% and 14% revenue growth for the full year.

"We have come a long way from our origins as a research-oriented company largely dependent on royalties," Marth said in a statement. "We sit here today with a large, diversified portfolio of customers--over 300-plus from large pharma, biotech and specialty--and have exposure to a growing customer base, as the pharmaceutical industry looks to optimize their R&D investments. Based on changes we have made over the last few years, AMRI is well-positioned to capture what we believe are attractive growth opportunities in a developing and growing market."

In the fourth quarter, AMRI posted total revenue of $67.1 million, virtually unchanged from the same period in 2012 as a 9% drop in royalties wiped away gains in contract sales. Net income came in at $4.5 million, above the prior year's $1.9 million.

AMRI finished out the year with about $176 million in cash, and Marth said the company will keep its eye out for deals that could further expand its business.

- read the full results

Suggested Articles

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.

Aetion has raised $50 million so far, and it plans to enhance its platform to support more complex therapeutic areas and expand its team.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.